This week in therapeutics

Indication	Target/marker/pathway	Summary	Licensing status	Publication and contact information
Cancer				
Ovarian cancer	Anti-Mullerian hormone receptor type II (AMHR2)	<p>Cell culture and mouse studies suggest that AMHR2 agonists could be used to treat ovarian cancer. Analysis of ascites fluid from ovarian cancer patients identified a subset of tumor cells with ectopic expression of stem cell-associated markers. In mouse xenograft models, ovarian tumor cell lines expressing the markers formed more rapidly than other ovarian tumor cell lines. In cell culture, anti-Mullerian hormone (AMH), which preferentially inhibits the growth of ovarian cancer stem cells, or a small molecule agonist of AMHR2 lowered the proliferation of tumor cells expressing the markers compared with that of other ovarian tumor cell lines. Next steps include scaling up production of recombinant AMH for clinical testing in ovarian cancer as an adjunct to chemotherapy.</p> <p>SciBX 3(42); doi:10.1038/scibx.2010.1264 Published online Oct. 28, 2010</p>	Patents pending; available for licensing	<p>Wei, X. <i>et al. Proc. Natl. Acad. Sci. USA</i>; published online Oct. 15, 2010; doi:10.1073/pnas.1012667107</p> <p>Contact: Patricia K. Donahoe, Massachusetts General Hospital, Boston, Mass. e-mail: pdonahoe@partners.org</p>